Table 3.
Predictors of the rates of microbiologically documented sterile site infection clinically documented infection and fever of unknown origin per course among intensive treatment courses (N = 101)
| |
Microbiological sterile site |
Clinically documented |
Fever of unknown origin |
|||
|---|---|---|---|---|---|---|
| |
Rate ratio |
P value |
Rate ratio |
P value |
Rate ratio |
P value |
| (CI) | (CI) | (CI) | ||||
|
Child characteristics at diagnosis |
|
|
|
|
||
| Age in years |
0.92 |
0.082 |
0.99 |
0.748 |
0.92 |
0.025 |
| (0.84, 1.01) |
|
(0.92, 1.06) |
|
(0.85, 0.99) |
|
|
| Obese vs. non-obese1 |
0.92 |
0.891 |
0.60 |
0.268 |
0.40 |
0.103 |
| (0.29, 2.93) |
|
(0.24, 1.48) |
|
(0.13, 1.20) |
|
|
|
Treatment characteristics |
|
|
|
|
|
|
| APL-specific treatment protocol |
0.77 |
0.643 |
2.63 |
0.127 |
0.69 |
0.496 |
| (0.25, 2.37) |
|
(0.76, 9.10) |
|
(0.24, 2.01) |
|
|
| Registered on study |
1.91 |
0.162 |
1.24 |
0.553 |
0.49 |
0.385 |
| (0.77, 4.70) |
|
(0.62, 2.48) |
|
(0.10, 2.43) |
|
|
| Diagnosed prior to January 1, 2000 |
3.18 |
0.030 |
1.22 |
0.691 |
2.87 |
0.018 |
| (1.12, 9.04) |
|
(0.46, 3.18) |
|
(1.20, 6.86) |
|
|
| Cumulative dose of cytarabine (g/m2) |
1.09 |
0.008 |
0.97 |
0.522 |
0.99 |
0.763 |
| (1.02, 1.16) |
|
(0.88, 1.07) |
|
(0.90, 1.08) |
|
|
|
Course characteristics |
|
|
|
|
|
|
| Neutropenia (ANC <0.5 ×109) at start of course |
0.99 |
0.990 |
5.68 |
<0.0001 |
1.36 |
0.436 |
| (0.32, 3.06) |
|
(2.42, 13.31) |
|
(0.63, 2.93) |
|
|
| Greater than 15 days with neutropenia |
2.04 |
0.208 |
4.18 |
0.001 |
2.01 |
0.138 |
| (0.67, 6.21) |
|
(1.81, 9.62) |
|
(0.80, 5.07) |
|
|
| Days receiving corticosteroids | 1.04 |
0.064 |
1.03 |
0.075 |
1.01 |
0.555 |
| (1.00, 1.09) | (1.00, 1.07) | (0.97, 1.05) | ||||
Abbreviations: APL acute promyelocytic leukemia, ANC absolute neutrophil count, CI confidence interval; 1 Obesity only available for children ≥ 2 years of age.